Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches

Expert Review of Respiratory Medicine

Volumn 10, Issue 6, 2016, Pages 685-697

  Lund Palau, Helena ^a   Turnbull, Andrew R ^a,b   Bush, Andrew ^a,b   Bardin, Emmanuelle ^c   Cameron, Loren ^c   Soren, Odel ^d   Wierre Gore, Natasha ^a   Alton, Eric W F W ^a   Bundy, Jacob G ^a   Connett, Gary ^e   Faust, Saul N ^e   Filloux, Alain ^f   Freemont, Paul ^c   Jones, Andy ^g   Khoo, Valerie ^a   Morales, Sandra ^h   Murphy, Ronan ^a   Pabary, Rishi ^a   Simbo, Ameze ^a   Schelenz, Silke ^g   Takats, Zoltan ^c   Webb, Jeremy ^g   Williams, Huw D ^e   Davies, Jane C ^a,b   more..

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g ROYAL BROMPTON HOSPITAL   (United Kingdom)

^h AmpliPhi Australia   (Australia)

Author keywords

airway; antibiotic; biofilm; cystic fibrosis; persistence; Pseudomonas aeruginosa; sputum

Indexed keywords

ANTIBIOTIC AGENT; MONOCLONAL ANTIBODY; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL CLEARANCE; BACTERIAL GROWTH; BACTERIAL VIRULENCE; BACTERIOPHAGE; BACTERIUM DETECTION; BIOFILM; CLINICAL PRACTICE; CYSTIC FIBROSIS; DISEASE PREDISPOSITION; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOTHERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PSEUDOMONAS INFECTION; QUORUM SENSING; REVIEW; SURFACE PROPERTY; SURVIVAL; CHRONIC DISEASE; COMPLICATION; MICROBIOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; CYSTIC FIBROSIS; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84975316985     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1080/17476348.2016.1177460     Document Type: Review

References (144)

1. R.T.Sadikot, T.S.Blackwell, J.W.Christman, et al. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med. 2005;171(11):1209–1223.
2. F.Aujoulat, F.Roger, A.Bourdier, et al. From environment to man: genome evolution and adaptation of human opportunistic bacterial pathogens. Genes (Basel). 2012;3(2):191–232.
3. T.Schwartz, H.Volkmann, S.Kirchen, et al. Real-time PCR detection of Pseudomonas aeruginosa in clinical and municipal wastewater and genotyping of the ciprofloxacin-resistant isolates. FEMS Microbiol Ecol. 2006;57(1):158–167.
4. E.Frimmersdorf, S.Horatzek, A.Pelnikevich, et al. How Pseudomonas aeruginosa adapts to various environments: a metabolomic approach. Environ Microbiol. 2010;12(6):1734–1747.
5. C.K.Stover, X.Q.Pham, A.L.Erwin, et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature. 2000;406(6799):959–964.•• The first complete sequence of a P. aeruginosa genome from the PAO1 laboratory strain, revealing genetic insights into its environmental adaptability and pathogenicity.
6. J.L.Burns, R.L.Gibson, S.McNamara, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis. 2001;183(3):444–452.
7. M.Rosenfeld, R.L.Gibson, S.McNamara, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol. 2001;32(5):356–366.
8. D.S.Armstrong, K.Grimwood, J.B.Carlin, et al. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol. 1996;21(5):267–275.
9. S.C.Langton Hewer, A.R.Smyth Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2014;11:Cd004197.
10. UK Cystic Fibrosis Registry. Annual data report 2013: Cystic Fibrosis Trust; 2014. Available from: http://www.cysticfibrosis.org.uk/media/598466/annual-data-report-2013-jul14.pdf.
11. Cystic Fibrosis Foundation Patient Registry. 2013 annual data report to the center directors. Bethesda, Maryland; 2014. Available from: https://www.cff.org/2013_CFF_Annual_Data_Report_to_the_Center_Directors.pdf.
12. M.W.Konstan, W.J.Morgan, S.M.Butler, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr. 2007;151(2):134–139, 9.e1.
13. J.Emerson, M.Rosenfeld, S.McNamara, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34(2):91–100.
14. G.M.Nixon, D.S.Armstrong, R.Carzino, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr. 2001;138(5):699–704.
15. R.L.Gibson, J.L.Burns, B.W.Ramsey. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168(8):918–951.
16. H.Matsui, B.R.Grubb, R.Tarran, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell. 1998;95(7):1005–1015.
17. R.Tarran, B.Button, M.Picher, et al. Normal and cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral infections. J Biol Chem. 2005;280(42):35751–35759.
18. H.Matsui, V.E.Wagner, D.B.Hill, et al. A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms. Proc Natl Acad Sci U S A. 2006;103(48):18131–18136.
19. D.A.Stoltz, D.K.Meyerholz, A.A.Pezzulo, et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med. 2010;2(29):29ra31.
20. N.W.Keiser, S.E.Birket, I.A.Evans, et al. Defective innate immunity and hyperinflammation in newborn cystic fibrosis transmembrane conductance regulator-knockout ferret lungs. Am J Respir Cell Mol Biol. 2015;52(6):683–694.
21. A.A.Pezzulo, X.X.Tang, M.J.Hoegger, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature. 2012;487(7405):109–113.
22. M.H.Abou Alaiwa, L.R.Reznikov, N.D.Gansemer, et al. pH modulates the activity and synergism of the airway surface liquid antimicrobials beta-defensin-3 and LL-37. Proc Natl Acad Sci U S A. 2014;111(52):18703–18708.
23. M.H.Abou Alaiwa, A.M.Beer, A.A.Pezzulo, et al. Neonates with cystic fibrosis have a reduced nasal liquid pH; a small pilot study. J Cyst Fibros. 2014;13(4):373–377.
24. D.McShane, J.C.Davies, M.G.Davies, et al. Airway surface pH in subjects with cystic fibrosis. Eur Respir J. 2003;21(1):37–42.
25. T.H.Schroeder, M.M.Lee, P.W.Yacono, et al. CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation. Proc Natl Acad Sci U S A. 2002;99(10):6907–6912.
26. G.B.Pier, M.Grout, T.S.Zaidi, et al. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science. 1996;271(5245):64–67.
27. H.C.Krivan, D.D.Roberts, V.Ginsburg. Many pulmonary pathogenic bacteria bind specifically to the carbohydrate sequence GalNAc beta 1-4Gal found in some glycolipids. Proc Natl Acad Sci U S A. 1988;85(16):6157–6161.
28. L.Saiman, A.Prince. Pseudomonas aeruginosa pili bind to asialoGM1 which is increased on the surface of cystic fibrosis epithelial cells. J Clin Invest. 1993;92(4):1875–1880.
29. J.C.Davies, M.Stern, A.Dewar, et al. CFTR gene transfer reduces the binding of Pseudomonas aeruginosa to cystic fibrosis respiratory epithelium. Am J Respir Cell Mol Biol. 1997;16(6):657–663.
30. R.S.Baltimore, C.D.Christie, G.J.Smith. Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration. Am Rev Respir Dis. 1989;140(6):1650–1661.
31. D.Worlitzsch, R.Tarran, M.Ulrich, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest. 2002;109(3):317–325.
32. L.Jelsbak, H.K.Johansen, A.L.Frost, et al. Molecular epidemiology and dynamics of Pseudomonas aeruginosa populations in lungs of cystic fibrosis patients. Infect Immun. 2007;75(5):2214–2224.
33. T.J.Kidd, K.A.Ramsay, S.Vidmar, et al. Pseudomonas aeruginosa genotypes acquired by children with cystic fibrosis by age 5-years. Journal of Cystic Fibrosis. 2015;14(3):361–369.•• Longitudinal study of P. aeruginosa acquisition, eradication success, and concordance of oropharyngeal and bronchoalveolar lavage (BAL) samples in preschool children with CF.
34. N.Cramer, L.Wiehlmann, O.Ciofu, et al. Molecular epidemiology of chronic Pseudomonas aeruginosa airway infections in cystic fibrosis. PLoS One. 2012;7(11):e50731.• Study comparing the molecular epidemiology of P. aeruginosa isolates from environmental and non-CF sources with cross-sectional and longitudinal isolates from CF patients in centers in Germany and Sweden.
35. P.C.Goeminne, T.S.Nawrot, K.De Boeck, et al. Proximity to blue spaces and risk of infection with Pseudomonas aeruginosa in cystic fibrosis: a case-control analysis. J Cyst Fibros. 2015;14(6):741–747.
36. K.J.Psoter, A.J.Der, J.Wakefield, et al. Association of meteorological and geographical factors and risk of initial Pseudomonas aeruginosa acquisition in young children with cystic fibrosis. Epidemiol Infect. 2016;144(5):1075–1083.
37. K.Cheng, R.L.Smyth, J.R.Govan, et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet. 1996;348(9028):639–642.
38. A.M.Jones, J.R.Govan, C.J.Doherty, et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet. 2001;358(9281):557–558.
39. D.S.Armstrong, G.M.Nixon, R.Carzino, et al. Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am J Respir Crit Care Med. 2002;166(7):983–987.
40. J.Zimakoff, N.Hoiby, K.Rosendal, et al. Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic. J Hosp Infect. 1983;4(1):31–40.
41. F.W.Scott, T.L.Pitt. Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales. J Med Microbiol. 2004;53(Pt 7):609–615.
42. S.D.Aaron, K.L.Vandemheen, K.Ramotar, et al. Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis. Jama. 2010;304(19):2145–2153.
43. A.M.Jones, J.R.Govan, C.J.Doherty, et al. Identification of airborne dissemination of epidemic multiresistant strains of Pseudomonas aeruginosa at a CF centre during a cross infection outbreak. Thorax. 2003;58(6):525–527.
44. S.Panagea, C.Winstanley, M.J.Walshaw, et al. Environmental contamination with an epidemic strain of Pseudomonas aeruginosa in a Liverpool cystic fibrosis centre, and study of its survival on dry surfaces. J Hosp Infect. 2005;59(2):102–107.
45. L.D.Knibbs, G.R.Johnson, T.J.Kidd, et al. Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosis. Thorax. 2014;69(8):740–745.• Study demonstrating viable P. aeruginosa in cough aerosols, which travel further and persist for longer than previously recognized, challenging the perceived wisdom on infection control.
46. Z.Li, M.R.Kosorok, P.M.Farrell, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. Jama. 2005;293(5):581–588.
47. J.G.Mainz, L.Naehrlich, M.Schien, et al. Concordant genotype of upper and lower airways P. aeruginosa and S. aureus isolates in cystic fibrosis. Thorax. 2009;64(6):535–540.
48. S.K.Hansen, M.H.Rau, H.K.Johansen, et al. Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. ISME J. 2012;6(1):31–45.
49. K.Aanaes. Bacterial sinusitis can be a focus for initial lung colonisation and chronic lung infection in patients with cystic fibrosis. J Cyst Fibros. 2013;12(Suppl 2):S1–S20.
50. R.Rivas Caldas, F.Le Gall, K.Revert, et al. Pseudomonas aeruginosa and periodontal pathogens in the oral cavity and lungs of cystic fibrosis patients: a case-control study. J Clin Microbiol. 2015;53(6):1898–1907.
51. R.Rivas Caldas, S.Boisramé. Upper aero-digestive contamination by Pseudomonas aeruginosa and implications in cystic fibrosis. Journal of Cystic Fibrosis. 2015;14(1):6–15.
52. J.G.Mainz, J.Hentschel, C.Schien, et al. Sinonasal persistence of Pseudomonas aeruginosa after lung transplantation. J Cyst Fibros. 2012;11(2):158–161.
53. G.B.Pier. Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity. Int J Med Microbiol. 2007;297(5):277–295.
54. R.K.Ernst, E.C.Yi, L.Guo, et al. Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science. 1999;286(5444):1561–1565.
55. M.Feldman, R.Bryan, S.Rajan, et al. Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection. Infect Immun. 1998;66(1):43–51.
56. G.A.O’Toole, R.Kolter. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol Microbiol. 1998;30(2):295–304.
57. F.Hayashi, K.D.Smith, A.Ozinsky, et al. The innate immune response to bacterial flagellin is mediated by toll-like receptor 5. Nature. 2001;410(6832):1099–1103.
58. M.C.Wolfgang, J.Jyot, A.L.Goodman, et al. Pseudomonas aeruginosa regulates flagellin expression as part of a global response to airway fluid from cystic fibrosis patients. Proc Natl Acad Sci U S A. 2004;101(17):6664–6668.
59. S.Bleves, V.Viarre, R.Salacha, et al. Protein secretion systems in Pseudomonas aeruginosa: a wealth of pathogenic weapons. Int J Med Microbiol. 2010;300(8):534–543.• A comprehensive review of P. aeruginosa secretion systems and their role in pathogenicity.
60. T.Bainbridge, R.B.FickJr. Functional importance of cystic fibrosis immunoglobulin G fragments generated by Pseudomonas aeruginosa elastase. J Lab Clin Med. 1989;114(6):728–733.
61. W.I.Mariencheck, J.F.Alcorn, S.M.Palmer, et al. Pseudomonas aeruginosa elastase degrades surfactant proteins A and D. Am J Respir Cell Mol Biol. 2003;28(4):528–537.
62. K.Kurahashi, O.Kajikawa, T.Sawa, et al. Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J Clin Invest. 1999;104(6):743–750.
63. B.Rada, T.L.Leto. Pyocyanin effects on respiratory epithelium: relevance in Pseudomonas aeruginosa airway infections. Trends Microbiol. 2013;21(2):73–81.
64. C.Nair, A.Shoemark, M.Chan, et al. Cyanide levels found in infected cystic fibrosis sputum inhibit airway ciliary function. Eur Respir J. 2014;44(5):1253–1261.
65. R.Wilson, T.Pitt, G.Taylor, et al. Pyocyanin and 1-hydroxyphenazine produced by Pseudomonas aeruginosa inhibit the beating of human respiratory cilia in vitro. J Clin Invest. 1987;79(1):221–229.
66. A.Filloux. Protein secretion systems in Pseudomonas aeruginosa: an essay on diversity, evolution, and function. Front Microbiol. 2011;2:155.
67. B.R.Kulasekara, H.D.Kulasekara, M.C.Wolfgang, et al. Acquisition and evolution of the exoU locus in Pseudomonas aeruginosa. J Bacteriol. 2006;188(11):4037–4050.
68. M.C.Wolfgang, B.R.Kulasekara, X.Liang, et al. Conservation of genome content and virulence determinants among clinical and environmental isolates of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A. 2003;100(14):8484–8489.
69. D.W.Wareham, M.A.Curtis. A genotypic and phenotypic comparison of type III secretion profiles of Pseudomonas aeruginosa cystic fibrosis and bacteremia isolates. Int J Med Microbiol. 2007;297(4):227–234.
70. A.R.Hauser. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Microbiol. 2009;7(9):654–665.
71. J.D.Mougous, M.E.Cuff, S.Raunser, et al. A virulence locus of Pseudomonas aeruginosa encodes a protein secretion apparatus. Science. 2006;312(5779):1526–1530.
72. N.Mayer-Hamblett, M.Rosenfeld, R.L.Gibson, et al. Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes. Am J Respir Crit Care Med. 2014;190(3):289–297.
73. D.W.Martin, M.J.Schurr, M.H.Mudd, et al. Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients. Proc Natl Acad Sci U S A. 1993;90(18):8377–8381.
74. K.Mathee, O.Ciofu, C.Sternberg, et al. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology. 1999;145(Pt 6):1349–1357.
75. M.Hentzer, G.M.Teitzel, G.J.Balzer, et al. Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J Bacteriol. 2001;183(18):5395–5401.
76. P.K.Singh, A.L.Schaefer, M.R.Parsek, et al. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature. 2000;407(6805):762–764.
77. T.Bjarnsholt, P.O.Jensen, M.J.Fiandaca, et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol. 2009;44(6):547–558.
78. C.Lopez-Causape, E.Rojo-Molinero, M.D.Macia, et al. The problems of antibiotic resistance in cystic fibrosis and solutions. Expert Rev Respir Med. 2015;9(1):73–88.
79. N.Hoiby, T.Bjarnsholt, M.Givskov, et al. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010;35(4):322–332.
80. J.W.Costerton, Z.Lewandowski, D.E.Caldwell, et al. Microbial biofilms. Annu Rev Microbiol. 1995;49:711–745.
81. J.A.Moscoso, H.Mikkelsen, S.Heeb, et al. The Pseudomonas aeruginosa sensor RetS switches type III and type VI secretion via c-di-GMP signalling. Environ Microbiol. 2011;13(12):3128–3138.
82. L.Yang, J.A.Haagensen, L.Jelsbak, et al. In situ growth rates and biofilm development of Pseudomonas aeruginosa populations in chronic lung infections. J Bacteriol. 2008;190(8):2767–2776.
83. S.S.Yoon, R.F.Hennigan, G.M.Hilliard, et al. Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis. Dev Cell. 2002;3(4):593–603.
84. M.J.Gambello, B.H.Iglewski. Cloning and characterization of the Pseudomonas aeruginosa lasR gene, a transcriptional activator of elastase expression. J Bacteriol. 1991;173(9):3000–3009.
85. J.P.Pearson, K.M.Gray, L.Passador, et al. Structure of the autoinducer required for expression of Pseudomonas aeruginosa virulence genes. Proc Natl Acad Sci U S A. 1994;91(1):197–201.
86. L.Passador, J.M.Cook, M.J.Gambello, et al. Expression of Pseudomonas aeruginosa virulence genes requires cell-to-cell communication. Science. 1993;260(5111):1127–1130.
87. U.A.Ochsner, A.K.Koch, A.Fiechter, et al. Isolation and characterization of a regulatory gene affecting rhamnolipid biosurfactant synthesis in Pseudomonas aeruginosa. J Bacteriol. 1994;176(7):2044–2054.
88. E.C.Pesci, J.P.Pearson, P.C.Seed, et al. Regulation of las and rhl quorum sensing in Pseudomonas aeruginosa. J Bacteriol. 1997;179(10):3127–3132.
89. D.G.Storey, E.E.Ujack, H.R.Rabin, et al. Pseudomonas aeruginosa lasR transcription correlates with the transcription of lasA, lasB, and toxA in chronic lung infections associated with cystic fibrosis. Infect Immun. 1998;66(6):2521–2528.
90. D.L.Erickson. Pseudomonas aeruginosa quorum-sensing systems may control virulence factor expression in the lungs of patients with cystic fibrosis. Infect Immun. 2002;70(4):1783–1790.
91. M.Whiteley, K.M.Lee, E.P.Greenberg. Identification of genes controlled by quorum sensing in Pseudomonas aeruginosa. Proc Natl Acad Sci U S A. 1999;96(24):13904–13909.
92. R.P.Smith. aeruginosa quorum-sensing systems and virulence. Curr Opin Microbiol. 2003;6(1):56–60.
93. P.Williams, M.Camara. Quorum sensing and environmental adaptation in Pseudomonas aeruginosa: a tale of regulatory networks and multifunctional signal molecules. Curr Opin Microbiol. 2009;12(2):182–191.
94. R.S.Smith, B.H.Iglewski. P. aeruginosa quorum-sensing systems and virulence. Curr Opin Microbiol. 2003;6(1):56–60.
95. E.C.Pesci, J.B.Milbank, J.P.Pearson, et al. Quinolone signaling in the cell-to-cell communication system of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A. 1999;96(20):11229–11234.
96. E.E.Smith, D.G.Buckley, Z.Wu, et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A. 2006;103(22):8487–8492.
97. L.R.Hoffman, H.D.Kulasekara, J.Emerson, et al. Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression. J Cyst Fibros. 2009;8(1):66–70.
98. T.Bjarnsholt, P.O.Jensen, T.H.Jakobsen, et al. Quorum sensing and virulence of Pseudomonas aeruginosa during lung infection of cystic fibrosis patients. PLoS One. 2010;5(4):e10115.
99. B.Ryall, M.Carrara, J.E.Zlosnik, et al. The mucoid switch in Pseudomonas aeruginosa represses quorum sensing systems and leads to complex changes to stationary phase virulence factor regulation. PLoS One. 2014;9(5):e96166.
100. W.H.Zhao, Z.Q.Hu. Beta-lactamases identified in clinical isolates of Pseudomonas aeruginosa. Crit Rev Microbiol. 2010;36(3):245–258.
101. K.Poole. Pseudomonas aeruginosa: resistance to the max. Front Microbiol. 2011;2:65.
102. J.M.Rodriguez-Martinez, L.Poirel, P.Nordmann. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53(11):4783–4788.
103. D.S.Armstrong, S.M.Hook, K.M.Jamsen, et al. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol. 2005;40(6):500–510.
104. B.Dhooghe, S.Noel, F.Huaux, et al. Lung inflammation in cystic fibrosis: pathogenesis and novel therapies. Clin Biochem. 2014;47(7–8):539–546.
105. R.G.Painter, V.G.Valentine, N.A.LansonJr., et al. CFTR expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis. Biochemistry. 2006;45(34):10260–10269.
106. R.L.Young, K.C.Malcolm, J.E.Kret, et al. Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR. PLoS One. 2011;6(9):e23637.
107. D.Hartl, P.Latzin, P.Hordijk, et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med. 2007;13(12):1423–1430.
108. M.Cohen-Cymberknoh, E.Kerem, T.Ferkol, et al. Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications. Thorax. 2013;68(12):1157–1162.
109. E.Pernet, L.Guillemot, P.R.Burgel, et al. Pseudomonas aeruginosa eradicates Staphylococcus aureus by manipulating the host immunity. Nat Commun. 2014;5:5105.
110. E.Kessler, M.Safrin, J.C.Olson, et al. Secreted LasA of Pseudomonas aeruginosa is a staphylolytic protease. J Biol Chem. 1993;268(10):7503–7508.
111. J.Kaur, B.P.Pethani, S.Kumar, et al. Pseudomonas aeruginosa inhibits the growth of Scedosporium aurantiacum, an opportunistic fungal pathogen isolated from the lungs of cystic fibrosis patients. Front Microbiol. 2015;6:866.
112. K.Smith, R.Rajendran, S.Kerr, et al. Aspergillus fumigatus enhances elastase production in Pseudomonas aeruginosa co-cultures. Med Mycol. 2015;53(7):645–655.
113. E.Lopez-Medina, D.Fan, L.A.Coughlin, et al. Candida albicans inhibits Pseudomonas aeruginosa virulence through suppression of pyochelin and pyoverdine biosynthesis. PLoS Pathog. 2015;11(8):e1005129.
114. S.S.Chattoraj, S.Ganesan, A.M.Jones, et al. Rhinovirus infection liberates planktonic bacteria from biofilm and increases chemokine responses in cystic fibrosis airway epithelial cells. Thorax. 2011;66(4):333–339.
115. C.E.Wainwright, S.Vidmar, D.S.Armstrong, et al. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA. 2011;306(2):163–171.
116. M.S.Muhlebach, M.B.Miller, C.Moore, et al. Are lower airway or throat cultures predictive of sinus bacteriology in cystic fibrosis? Pediatr Pulmonol. 2006;41(5):445–451.
117. T.A.Douglas, S.Brennan, L.Berry, et al. Value of serology in predicting Pseudomonas aeruginosa infection in young children with cystic fibrosis. Thorax. 2010;65(11):985–990.
118. M.Kappler, F.Nagel, M.Feilcke, et al. Predictive values of antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis one year after early eradication treatment. J Cyst Fibros. 2014;13(5):534–541.
119. R.Pabary, J.Huang, S.Kumar, et al. Does mass spectrometric breath analysis detect Pseudomonas aeruginosa in cystic fibrosis? Eur Respir J. 2016;47(3):994–997.
120. F.J.Gilchrist, R.J.Bright-Thomas, A.M.Jones, et al. Hydrogen cyanide concentrations in the breath of adult cystic fibrosis patients with and without Pseudomonas aeruginosa infection. J Breath Res. 2013;7(2):026010.
121. C.Vogelberg, T.Hirsch, A.Rosen-Wolff, et al. Pseudomonas aeruginosa and Burkholderia cepacia cannot be detected by PCR in the breath condensate of patients with cystic fibrosis. Pediatr Pulmonol. 2003;36(4):348–352.
122. N.Strittmatter, M.Rebec, E.A.Jones, et al. Characterization and identification of clinically relevant microorganisms using rapid evaporative ionization mass spectrometry. Anal Chem. 2014;86(13):6555–6562.
123. A.Ashish, M.Shaw, C.Winstanley, et al. Halting the spread of epidemic Pseudomonas aeruginosa in an adult cystic fibrosis centre: a prospective cohort study. JRSM Short Rep. 2013;4(1):1.
124. J.Zhao, P.D.Schloss, L.M.Kalikin, et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A. 2012;109(15):5809–5814.
125. S.Boutin, S.Y.Graeber, M.Weitnauer, et al. Comparison of microbiomes from different niches of upper and lower airways in children and adolescents with cystic fibrosis. PLoS One. 2015;10(1):e0116029.
126. P.J.MogayzelJr., E.T.Naureckas, K.A.Robinson, et al. Cystic fibrosis foundation pulmonary guideline. Pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann Am Thorac Soc. 2014;11(10):1640–1650.
127. F.Ratjen, A.Munck, P.Kho, et al. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax. 2010;65(4):286–291.• Randomized trial comparing 28 and 56 days of inhaled tobramycin for eradication of early P. aeruginosa infection, showing comparable efficacy.
128. G.A.Tramper-Stranders, T.F.Wolfs, S.Van Haren Noman, et al. Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Thorax. 2010;65(10):915–920.
129. V.Waters, S.Stanojevic, E.G.Atenafu, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J. 2012;40(1):61–66.
130. K.De Boer, K.L.Vandemheen, E.Tullis, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax. 2011;66(8):680–685.
131. D.B.Sanders, R.C.Bittner, M.Rosenfeld, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med. 2010;182(5):627–632.
132. V.Waters, E.G.Atenafu, J.G.Salazar, et al. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. J Cyst Fibros. 2012;11(1):8–13.
133. S.D.Aaron, K.L.Vandemheen, W.Ferris, et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet. 2005;366(9484):463–471.
134. T.W.R.Lee, K.G.Brownlee, S.P.Conway, et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. Journal of Cystic Fibrosis. 2003;2(1):29–34.
135. A.Equi, I.M.Balfour-Lynn, A.Bush, et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002;360(9338):978–984.
136. A.R.Smyth, P.M.Cifelli, C.A.Ortori, et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis–a pilot randomized controlled trial. Pediatr Pulmonol. 2010;45(4):356–362.
137. N.Barraud, D.J.Hassett, S.H.Hwang, et al. Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa. J Bacteriol. 2006;188(21):7344–7353.
138. N.Barraud, B.G.Kardak, N.R.Yepuri, et al. Cephalosporin-3ʹ-diazeniumdiolates: targeted NO-donor prodrugs for dispersing bacterial biofilms. Angew Chem Int Ed Engl. 2012;51(36):9057–9060.
139. A.Wright, C.H.Hawkins, E.E.Anggard, et al. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol. 2009;34(4):349–357.
140. R.Pabary, C.Singh, S.Morales, et al. Anti-pseudomonal bacteriophage reduces infective burden and inflammatory response in murine lung. Antimicrob Agents Chemother. 2015;60(2):744–751.
141. L.Debarbieux, D.Leduc, D.Maura, et al. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis. 2010;201(7):1096–1104.
142. T.Secher, S.Fas, L.Fauconnier, et al. The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem. PLoS One. 2013;8(9):e73396.
143. H.K.Johansen, P.C.Gotzsche. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev. 2013;6:Cd001399.
144. S.L.Heltshe, N.Mayer-Hamblett, J.L.Burns, et al. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect Dis. 2015;60(5):703–712.